On the occasion of the 7th ACTC meeting, Molecular Oncology will initiate a new article collection on the general thematic area of ‘Liquid Biopsies’!
After the 7th ACTC meeting, participants are welcome to submit their latest research in the field of Liquid Biopsy to Molecular Oncology. Manuscripts may be submitted in the format of a Research Article, Short Report, or Method using THIS LINK. For more details on article types, please check the journal’s author guidelines.
Manuscripts will be editorially assessed based on novelty and completeness and will be subject to a regular peer review process. Accepted articles will be published continuously and featured in the special ACTC/Liquid Biopsy article collection.
Molecular Oncology is an open-access journal that publishes studies from across the cancer research continuum. It is owned by the charitable organization FEBS, which reinvests the full journal income to support young researchers through courses and fellowships. Molecular Oncology publishes 200 – 300 articles per year (with Review articles representing less than 10% of the content) and has an Impact Factor of 7,449. The journal has format-free submission requirements, and the median time to make the first decision is 37 days for peer-reviewed articles (in 2025). Publication fees may be covered through the Wiley agreements with your institute or funder
After the 7th ACTC meeting, participants are welcome to submit their latest research in the field of Liquid Biopsy to Molecular Oncology. Manuscripts may be submitted in the format of a Research Article, Short Report, or Method using THIS LINK. For more details on article types, please check the journal’s author guidelines.
Manuscripts will be editorially assessed based on novelty and completeness and will be subject to a regular peer review process. Accepted articles will be published continuously and featured in the special ACTC/Liquid Biopsy article collection.
Molecular Oncology is an open-access journal that publishes studies from across the cancer research continuum. It is owned by the charitable organization FEBS, which reinvests the full journal income to support young researchers through courses and fellowships. Molecular Oncology publishes 200 – 300 articles per year (with Review articles representing less than 10% of the content) and has an Impact Factor of 7,449. The journal has format-free submission requirements, and the median time to make the first decision is 37 days for peer-reviewed articles (in 2025). Publication fees may be covered through the Wiley agreements with your institute or funder